Nothing Special   »   [go: up one dir, main page]

PL3746446T3 - Inhibitory PRC2 - Google Patents

Inhibitory PRC2

Info

Publication number
PL3746446T3
PL3746446T3 PL19710816.0T PL19710816T PL3746446T3 PL 3746446 T3 PL3746446 T3 PL 3746446T3 PL 19710816 T PL19710816 T PL 19710816T PL 3746446 T3 PL3746446 T3 PL 3746446T3
Authority
PL
Poland
Prior art keywords
prc2
inhibitors
prc2 inhibitors
Prior art date
Application number
PL19710816.0T
Other languages
English (en)
Inventor
Matthew Arnold Marx
Matthew Randolph Lee
Thomas P. Bobinski
Aaron Craig BURNS
Nidhi Arora
James Gail Christensen
John Michael Ketcham
Original Assignee
Mirati Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics, Inc. filed Critical Mirati Therapeutics, Inc.
Publication of PL3746446T3 publication Critical patent/PL3746446T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PL19710816.0T 2018-01-31 2019-01-29 Inhibitory PRC2 PL3746446T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862624176P 2018-01-31 2018-01-31
US201862672701P 2018-05-17 2018-05-17
US201862747736P 2018-10-19 2018-10-19
PCT/US2019/015677 WO2019152419A1 (en) 2018-01-31 2019-01-29 Prc2 inhibitors

Publications (1)

Publication Number Publication Date
PL3746446T3 true PL3746446T3 (pl) 2022-08-29

Family

ID=65763738

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19710816.0T PL3746446T3 (pl) 2018-01-31 2019-01-29 Inhibitory PRC2

Country Status (19)

Country Link
US (4) US11485738B2 (pl)
EP (2) EP3746446B1 (pl)
JP (3) JP7025556B2 (pl)
KR (2) KR20220139439A (pl)
CN (1) CN112004816B (pl)
AU (2) AU2019214861B2 (pl)
BR (1) BR112020015583B1 (pl)
CA (1) CA3089639C (pl)
DK (2) DK3746446T3 (pl)
ES (1) ES2923290T3 (pl)
FI (1) FI4043466T3 (pl)
HU (1) HUE059536T2 (pl)
IL (2) IL276156B (pl)
MX (2) MX2020007974A (pl)
NZ (1) NZ766447A (pl)
PL (1) PL3746446T3 (pl)
PT (2) PT3746446T (pl)
WO (1) WO2019152419A1 (pl)
ZA (2) ZA202004453B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3746446T3 (da) * 2018-01-31 2022-06-27 Mirati Therapeutics Inc PRC2-inhibitorer
MX2021006026A (es) * 2018-11-30 2021-07-06 Tuojie Biotech Shanghai Co Ltd Pirimidina y derivado heterociclico de nitrogeno de cinco miembros, metodo de preparacion y usos medicos de los mismos.
EP3980422A1 (en) * 2019-06-05 2022-04-13 Mirati Therapeutics, Inc. Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer
CN112409385B (zh) * 2019-08-22 2024-08-13 上海青煜医药科技有限公司 氮杂芳基化合物及其应用
CN113004233B (zh) * 2019-12-18 2022-12-20 南京优氟医药科技有限公司 一种用于制备prc2抑制剂的化合物、其制备方法和用途
CN114907385A (zh) 2021-02-10 2022-08-16 上海青煜医药科技有限公司 氮杂芳基化合物、其制备方法及应用
WO2023049724A1 (en) * 2021-09-24 2023-03-30 Oric Pharmaceuticals, Inc. Prc2 inhibitors for use in treating blood disorders
WO2024059607A1 (en) * 2022-09-14 2024-03-21 Oric Pharmaceuticals, Inc. Physical forms of an inhibitor of prc2
GB202216323D0 (en) 2022-11-02 2022-12-14 Cerevance Ltd Novel compounds
WO2024123669A1 (en) * 2022-12-05 2024-06-13 Oric Pharmaceuticals, Inc. Treatment of prostate cancer having androgen receptor variants
WO2024148008A1 (en) * 2023-01-03 2024-07-11 Oric Pharmaceuticals, Inc. Treatment of neuroendocrine prostate cancer
WO2024215699A1 (en) * 2023-04-11 2024-10-17 Oric Pharmaceuticals, Inc. Treatment of t-cell lymphoma

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921762B2 (en) 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
WO2010021381A1 (ja) 2008-08-22 2010-02-25 武田薬品工業株式会社 縮合複素環誘導体およびその用途
UA110112C2 (uk) 2010-05-07 2015-11-25 Глаксосмітклайн Ллс Індоли
ES2534804T3 (es) 2010-05-07 2015-04-28 Glaxosmithkline Llc Indazoles
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
WO2012082436A2 (en) 2010-12-03 2012-06-21 Epizyme, Inc. Modulators of histone methyltransferase, and methods of use thereof
WO2012118812A2 (en) 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
MX361350B (es) 2011-05-10 2018-12-04 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal de sodio.
KR20140082742A (ko) 2011-09-30 2014-07-02 글락소스미스클라인 엘엘씨 암을 치료하는 방법
EP2771343B1 (en) 2011-10-27 2016-07-13 Memorial Sloan-Kettering Cancer Center Methyltransferase inhibitors for treating cancer
WO2013075084A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US9206128B2 (en) 2011-11-18 2015-12-08 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP2812001B1 (en) 2012-02-10 2017-06-14 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
IL308807A (en) 2012-04-13 2024-01-01 Epizyme Inc Combined treatment for cancer
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
US9105490B2 (en) 2012-09-27 2015-08-11 Taiwan Semiconductor Manufacturing Company, Ltd. Contact structure of semiconductor device
US20150239842A1 (en) 2012-09-28 2015-08-27 Pfizer Inc. Benzamide and heterobenzamide compounds
EP3725314A1 (en) 2012-10-15 2020-10-21 Epizyme, Inc. Substituted benzene compounds
MX2015004771A (es) 2012-10-15 2016-01-08 Epizyme Inc Metodos para tratar cancer.
EP2931707A4 (en) 2012-12-13 2016-07-20 Glaxosmithkline Llc AMPLIFIER OF ZEST HOMOLOG 2 INHIBITORS
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
WO2014100646A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone compounds
EP2935264B1 (en) 2012-12-21 2017-10-18 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
TWI629273B (zh) 2013-02-11 2018-07-11 美商星宿藥物公司 甲基修飾酵素之調節劑、其組成物及用途
US9045477B2 (en) 2013-03-15 2015-06-02 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2014151142A1 (en) 2013-03-15 2014-09-25 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP2970306A4 (en) 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS CONDENSED IN 6.5
US9243001B2 (en) 2013-03-15 2016-01-26 Epizyme, Inc. Substituted benzene compounds
EP2970281A4 (en) 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED BENZENE COMPOUNDS
US9505745B2 (en) 2013-04-30 2016-11-29 Glaxosmithkline Intellectual Property (No. 2) Limited Enhancer of zeste homolog 2 inhibitors
AU2014276417B2 (en) 2013-06-06 2016-11-24 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of Zeste Homolog 2 inhibitors
RU2016104044A (ru) 2013-07-10 2017-08-15 Глэксосмитклайн Интеллекчуал Проперти (Nо.2) Лимитед Ингибиторы усилителя zeste гомолога 2
WO2015010078A2 (en) 2013-07-19 2015-01-22 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
US10150764B2 (en) 2013-07-19 2018-12-11 Epizyme, Inc. Substituted benzene compounds
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
US9738630B2 (en) 2013-11-19 2017-08-22 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
WO2015077194A1 (en) 2013-11-22 2015-05-28 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
EP3111222A1 (en) 2014-02-26 2017-01-04 Glaxosmithkline Intellectual Property (No. 2) Limited Methods of treating cancer patients responding to ezh2 inhibitor gsk126
KR20160122266A (ko) 2014-03-07 2016-10-21 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 제스트 인핸서 상동체 2 억제제
SG11201607006TA (en) 2014-03-17 2016-10-28 Daiichi Sankyo Co Ltd 1,3-benzodioxole derivative
PL3157915T3 (pl) 2014-06-17 2019-07-31 Pfizer Inc. Podstawione związki dihydroizochinolinonowe
WO2015193768A1 (en) 2014-06-17 2015-12-23 Pfizer Inc. Aryl fused lactams as ezh2 modulators
MA40848A (fr) 2014-10-28 2021-05-05 Glaxosmithkline Ip No 2 Ltd Inhibiteurs d'ezh2 (enhancer of zeste homolog 2)
US11236082B2 (en) 2014-11-06 2022-02-01 Dana-Farber Cancer Institute, Inc. EZH2 inhibitors and uses thereof
CA2966336A1 (en) 2014-11-06 2016-05-12 Dana-Farber Cancer Institute, Inc. Use of compositions modulating chromatin structure for graft versus host disease (gvhd)
AR102767A1 (es) 2014-12-05 2017-03-22 Lilly Co Eli Inhibidores de ezh2
WO2016102493A1 (en) 2014-12-22 2016-06-30 Bayer Pharma Aktiengesellschaft Imidazopyridine ezh2 inhibitors
ES2722048T3 (es) 2014-12-23 2019-08-07 Novartis Ag Compuestos de triazolopirimidina y usos de los mismos
IL236420A (en) * 2014-12-23 2016-06-30 Ron Schneider Methods and systems for producing an enlarged 3D image
JP6636031B2 (ja) 2015-01-30 2020-01-29 ジェネンテック, インコーポレイテッド 治療用化合物およびその使用
US20180037568A1 (en) 2015-02-13 2018-02-08 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ezh2抑制劑
PT3378859T (pt) 2015-11-19 2019-12-11 Jiangsu Hengrui Medicine Co Derivado de benzofurano, método de preparação do mesmo e uso do mesmo em medicina
CA3007492A1 (en) 2015-12-07 2017-06-15 Epizyme, Inc. Inhibitors of ezh2 and methods of use thereof
WO2017174023A1 (zh) 2016-04-08 2017-10-12 南京明德新药研发股份有限公司 作为ezh2抑制剂的联苯化合物
JP7493304B2 (ja) 2016-04-22 2024-05-31 ダナ-ファーバー キャンサー インスティテュート, インコーポレイテッド Ezh2インヒビターおよびそれらの使用
SG11201809560QA (en) 2016-05-05 2018-11-29 Glaxosmithkline Ip No 2 Ltd Enhancer of zeste homolog 2 inhibitors
US9957274B2 (en) 2016-05-06 2018-05-01 Abbvie Inc. Indane inhibitors of EED and methods of their use
EP3464643A4 (en) 2016-06-01 2020-04-01 Epizyme Inc USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER
US11147819B2 (en) 2016-06-17 2021-10-19 Epizyme, Inc. EZH2 inhibitors for treating cancer
EP3472161B1 (en) 2016-06-20 2020-03-25 Novartis AG Triazolopyridine compounds and uses thereof
CN109790166A (zh) * 2016-06-20 2019-05-21 诺华股份有限公司 咪唑并吡啶化合物用于治疗癌症
IL263429B (en) * 2016-06-20 2022-08-01 Novartis Ag Crystalline forms of a triazolopyrimidine compound
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
WO2019062435A1 (zh) 2017-09-28 2019-04-04 中国科学院上海药物研究所 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
CN109942556A (zh) 2017-12-21 2019-06-28 上海青煜医药科技有限公司 嘧啶酮化合物及其应用
DK3746446T3 (da) 2018-01-31 2022-06-27 Mirati Therapeutics Inc PRC2-inhibitorer
CN110156787B (zh) 2018-02-13 2021-11-02 中国科学院上海药物研究所 一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途
CN110563722A (zh) 2018-06-06 2019-12-13 上海青煜医药科技有限公司 吡啶或哒嗪并环化合物及其应用
US20220213097A1 (en) 2019-04-22 2022-07-07 Mirati Therapeutics, Inc. Naphthyridine derivatives as prc2 inhibitors
EP3980422A1 (en) 2019-06-05 2022-04-13 Mirati Therapeutics, Inc. Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer

Also Published As

Publication number Publication date
CN112004816A (zh) 2020-11-27
BR112020015583B1 (pt) 2022-12-06
CA3089639C (en) 2024-06-18
NZ766447A (en) 2021-12-24
WO2019152419A1 (en) 2019-08-08
DK3746446T3 (da) 2022-06-27
JP2023109962A (ja) 2023-08-08
AU2021266351A1 (en) 2021-12-09
US20210101904A1 (en) 2021-04-08
US20210230168A1 (en) 2021-07-29
KR20220139439A (ko) 2022-10-14
AU2019214861A1 (en) 2020-08-13
KR102451529B1 (ko) 2022-10-06
DK4043466T3 (da) 2024-09-30
IL276156B (en) 2021-08-31
KR20200115570A (ko) 2020-10-07
BR112020015583A2 (pt) 2021-02-02
EP4043466B1 (en) 2024-08-21
JP7288527B2 (ja) 2023-06-07
NZ783240A (en) 2024-04-26
ZA202107835B (en) 2022-07-27
WO2019152419A8 (en) 2019-11-07
CN112004816B (zh) 2024-01-05
AU2019214861B2 (en) 2021-11-18
EP3746446B1 (en) 2022-05-11
IL276156A (en) 2020-09-30
MX2021012501A (es) 2021-11-12
PT4043466T (pt) 2024-10-14
ES2923290T3 (es) 2022-09-26
IL285354B (en) 2022-06-01
US11485738B2 (en) 2022-11-01
MX2020007974A (es) 2020-09-07
US11091495B2 (en) 2021-08-17
FI4043466T3 (fi) 2024-10-30
AU2021266351B2 (en) 2022-11-24
US11220509B2 (en) 2022-01-11
US20230137025A1 (en) 2023-05-04
IL285354A (en) 2021-09-30
US20210032252A1 (en) 2021-02-04
PT3746446T (pt) 2022-07-18
EP3746446A1 (en) 2020-12-09
EP4043466A1 (en) 2022-08-17
ZA202004453B (en) 2022-11-30
JP7025556B2 (ja) 2022-02-24
CA3089639A1 (en) 2019-08-08
JP7495555B2 (ja) 2024-06-04
JP2022068252A (ja) 2022-05-09
JP2021512092A (ja) 2021-05-13
HUE059536T2 (hu) 2022-11-28

Similar Documents

Publication Publication Date Title
IL283639A (en) kif18a inhibitors
ZA202107835B (en) Prc2 inhibitors
IL277006A (en) CD73 inhibitors
IL269196A (en) New inhibitors
IL304348A (en) cd73 inhibitors
IL276813A (en) Arginase inhibitors
GB201807014D0 (en) Factor xlla inhibitors
SG11202010347XA (en) Stat3 inhibitors
ZA201907136B (en) Ip6k inhibitors
IL276013A (en) pi4kiiibeta inhibitors
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors
IL274550A (en) Dopamine-B-hydroxylase inhibitors
GB201807845D0 (en) Kinase Inhibitors
GB201812462D0 (en) Inhibitors
GB201804439D0 (en) Dopamin-b-hydroxylase inhibitors
GB201908044D0 (en) Dopamine-B-Hydroxylase inhibitors
GB201905476D0 (en) MAPA4K4 Inhibitors
EP3863638C0 (en) PHOSPHODIESTERASE INHIBITORS
GB201809939D0 (en) Eastase inhibitor
GB201721465D0 (en) Inhibitors
GB201720189D0 (en) Dopamine-B-hydroxylase inhibitors